Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ombitasvir/paritaprevir/ritonavir - AbbVie/Enanta Pharmaceuticals

Drug Profile

Ombitasvir/paritaprevir/ritonavir - AbbVie/Enanta Pharmaceuticals

Alternative Names: ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); VIEKIRA XR; Viekirax

Latest Information Update: 19 Dec 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Amides; Anilides; Antiretrovirals; Antivirals; Aza compounds; Carbamates; Cyclopropanes; Phenanthridines; Pyrroles; Pyrrolidines; Small molecules; Sulfones; Thiazoles
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 13 Nov 2017 Abbvie terminates a phase III trial in Hepatitis C (Second-line or greater therapy) in USA and Spain due to low enrolment (PO) (NCT02504099) (EudraCT2015-001049-10)
  • 14 Jul 2017 AbbVie completes a phase II trial for Hepatitis C (Combination therapy with sofosbuvir ± ribavirin, In patients with genotype 3 hepatitis C, without cirrhosis) in Australia, Canada, New Zealand and United Kingdom (PO) (NCT02292719)
  • 07 Jul 2017 AbbVie completes a phase II trial for Hepatitis C (Combination therapy, treatment-experienced) in USA (PO) (NCT02356562)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top